| Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study K Selmaj, DKB Li, HP Hartung, B Hemmer, L Kappos, MS Freedman, ... The Lancet Neurology 12 (8), 756-767, 2013 | 282 | 2013 |
| Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy G Francis, L Kappos, P O¢connor, W Collins, D Tang, F Mercier, JA Cohen Multiple Sclerosis Journal 20 (4), 471-480, 2014 | 140 | 2014 |
| Rivastigmine exposure provided by a transdermal patch versus capsules F Mercier, G Lefèvre, HL Aaron Huang, H Schmidli, B Amzal, ... Current medical research and opinion 23 (12), 3199-3204, 2007 | 93 | 2007 |
| Evaluation of tumor size response metrics to predict survival in oncology clinical trials R Bruno, F Mercier, L Claret Clinical Pharmacology & Therapeutics 95 (4), 386-393, 2014 | 68 | 2014 |
| Using historical control information for the design and analysis of clinical trials with overdispersed count data S Gsteiger, B Neuenschwander, F Mercier, H Schmidli Statistics in Medicine 32 (21), 3609-3622, 2013 | 59 | 2013 |
| Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO E Gibiansky, C Petry, F Mercier, A Günther, A Herman, L Kappos, ... British journal of clinical pharmacology 87 (6), 2511-2520, 2021 | 46 | 2021 |
| A model-based meta-analysis to compare efficacy and tolerability of tramadol and tapentadol for the treatment of chronic non-malignant pain F Mercier, L Claret, K Prins, R Bruno Pain and therapy 3, 31-44, 2014 | 43 | 2014 |
| Population pharmacokinetic analysis and exploratory exposure–bleeding rate relationship of emicizumab in adult and pediatric persons with hemophilia A S Retout, C Schmitt, C Petry, F Mercier, N Frey Clinical Pharmacokinetics 59, 1611-1625, 2020 | 37 | 2020 |
| Association between tumor size kinetics and survival in patients with urothelial carcinoma treated with atezolizumab: implication for patient follow‐up C Tardivon, S Desmée, M Kerioui, R Bruno, B Wu, F Mentré, F Mercier, ... Clinical Pharmacology & Therapeutics 106 (4), 810-820, 2019 | 36 | 2019 |
| Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer PN Morcos, E Nueesch, F Jaminion, E Guerini, JC Hsu, W Bordogna, ... Cancer Chemotherapy and Pharmacology 82, 129-138, 2018 | 27 | 2018 |
| Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors G Meneses-Lorente, D Bentley, E Guerini, K Kowalski, E Chow-Maneval, ... Investigational New Drugs 39, 803-811, 2021 | 22 | 2021 |
| Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients L Claret, F Mercier, BE Houk, PA Milligan, R Bruno Cancer chemotherapy and pharmacology 76, 567-573, 2015 | 22 | 2015 |
| Estimating time to disease progression comparing transition models and survival methods—An analysis of multiple sclerosis data M Mandel, F Mercier, B Eckert, P Chin, RA Betensky Biometrics 69 (1), 225-234, 2013 | 21 | 2013 |
| Population pharmacokinetics of fingolimod phosphate in healthy participants K Wu, F Mercier, OJ David, RL Schmouder, M Looby The Journal of Clinical Pharmacology 52 (7), 1054-1068, 2012 | 20 | 2012 |
| Lymphocytes and fingolimod-temporal pattern and relationship with infections G Francis, L Kappos, P O'Connor, W Collins, L Zhang-Auberson, ... NEUROLOGY 76 (9), A374-A374, 2011 | 20 | 2011 |
| Exposure–bleeding count modeling of emicizumab for the prophylaxis of bleeding in persons with hemophilia A with/without inhibitors against factor VIII F Jonsson, C Schmitt, C Petry, F Mercier, N Frey, S Retout Clinical Pharmacokinetics 60, 931-941, 2021 | 18 | 2021 |
| Characterization of dose‐response for count data using a generalized MCP‐Mod approach in an adaptive dose‐ranging trial F Mercier, B Bornkamp, D Ohlssen, E Wallstroem Pharmaceutical Statistics 14 (4), 359-367, 2015 | 17 | 2015 |
| Model‐based drug development in oncology: what's next? R Bruno, F Mercier, L Claret Clinical Pharmacology & Therapeutics 93 (4), 303-305, 2013 | 17 | 2013 |
| Bayesian inference using Hamiltonian Monte‐Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy M Kerioui, F Mercier, J Bertrand, C Tardivon, R Bruno, J Guedj, S Desmée Statistics in Medicine 39 (30), 4853-4868, 2020 | 16 | 2020 |
| Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis SL Hauser, A Bar-Or, MS Weber, H Kletzl, A Günther, M Manfrini, F Model, ... Neurology: Neuroimmunology & Neuroinflammation 10 (2), e200094, 2023 | 13 | 2023 |
Rene BrunoGenentech/RocheVerified email at roche.com
